Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 17/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190936 | 0.91 | APP (0.79) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL4380573 | 0.91 | APP (0.79) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL14190926 | 0.90 | APP (0.79) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL4381093 | 0.90 | APP (0.79) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL2830260 | 0.83 | APP (0.82) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL3780738 | 0.83 | APP (0.69) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL3780737 | 0.83 | APP (0.69) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL4976275 | 0.75 | APP (0.59) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL4976265 | 0.75 | APP (0.59) | APPKDM4EMEN1HPGDKMT2A | |
| SCHEMBL14218033 | 0.75 | APP (0.81) | APPKDM4EMEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |